Khalid Orayj B.Pharm, PharmD, PhD King Khalid University College of Pharmacy

# **EDUCATION**

4/2020	<b>Doctor of Philosophy (PhD)</b> Cardiff University, School of Pharmacy and Pharmaceutical Sciences
5/2015	<i>Doctor of Pharmacy (PharmD)</i> Massachusetts College of Pharmacy and Health Sciences University (Worcester, MA)
4/2010	<b>Bachelor of Science (BSc) in Pharmaceutical Sciences</b> King Khalid University (Abha, Saudi Arabia)

### **PROFESSIONAL LICENSES**

2011-current	Saudi Pharmacy license
2012-2015	Massachusetts Pharmacy Intern License

# **EXPERIENTIAL EDUCATION**

2017-2020	Medical Researcher	Cardiff Parkinson's Clinic, UK
2016	Hospital Trainee Preceptor	Military Hospital, KSA
2015	<b>Research Pharmacy Intern</b>	Umass Memorial Hospital, USA
2015	Ambulatory Pharmacy Intern	Edward M Kennedy Center, USA
2014	Institutional Pharmacy Intern	Good Samaritan Medical Center, USA
2013	Institutional Pharmacy Intern	Heywood Hospital, USA
2013	Community Pharmacy Intern	Stop&shop Pharmacy, USA
2010	Institutional Pharmacy Intern	Asir Regional Hospital, KSA

### AWARDS

•11/2010 Abha Prize Certificate of Achievement, Abha, Saudi Arabia.

•2007, 2008, 2009 Certificate of Appreciation for participating student activities from King Khalid University, Saudi Arabia.

•9/2007 Certificate of Excellence from King Khalid University, Saudi Arabia.

•9/2007 Certificate of Thanks and Appreciation from the Saudi Pharmaceutical Society for participating in the Second Summer Meeting, Saudi Arabia.

### **PROFESSIONAL MEMBERSHIP:**

- A member in the International Parkinson and Movement Disorder Society (MDS).
- A member in the European Academy of Neurology (EAN)

#### PUBLICATIONS

Orayj, Khalid. "Cardiovascular Events Associated with Antipsychotics in Newly Diagnosed Parkinson's Disease Patients: A Propensity Score Matched Cohort Study." *International Journal of General Medicine* 14 (2021): 2975.

Orayj, Khalid, et al. "The Use of Over-The-Counter (OTC) Medications by University Students During Examinations in Saudi Arabia: A Cross-Sectional Study." *Risk Management and Healthcare Policy* 14 (2021): 2675.

Orayj, Khalid. "Impact of Antidepressants on Cardiac Events and All-Cause Mortality in Parkinson's Disease: A National Data-Linkage Study." *Neuropsychiatric Disease and Treatment* 17 (2021): 2499.

Orayj, Khalid. "Trends and Contributing Factors for Prescribing Antipsychotics in Newly Diagnosed Parkinson's Disease Patients: A Population-Based Study." Risk Management and Healthcare Policy 14 (2021): 2443.

Orayj, Khalid, et al. "Factors affecting the choice of first-line therapy in Parkinson's disease patients in Wales: A population-based study." Saudi Pharmaceutical Journal 29.2 (2021): 206-212.

Orayj K, Akbari A, Lacey A, Pickrell O, Smith M, Lane E. The relationship between first-line therapy in Parkinson's disease patients and social deprivation status, does a delay in PD diagnosis mediate this relationship? (2020), Oral Presentations. Int J Pharm Pract, 28: 4-43. doi:10.1111/jpp.12606

Khalid Orayj and Emma Lane, "Patterns and Determinants of Prescribing for Parkinson's Disease: A Systematic Literature Review," Parkinson's Disease, vol. 2019, Article ID 9237181, 40 pages, 2019. <u>https://doi.org/10.1155/2019/9237181</u>.

K. Orayj, A. Lacey, A. Akbari, O. Pickrell, E. Lane. Trends in first line therapy for PD in Wales: A 16 year observational study [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/trends-in-first-line-therapy-for-pd-in-wales-a-16-year-observational-study/. Accessed September 27, 2019.

Orayj K, Akbari A, Lacey A, Pickrell O, Smith M, Lane E. Incidence and prevalence of Parkinson's disease (PD) in Wales. Eur J Neurol. 2019;26 Suppl 1:331.